NASDAQ · Biotechnology

Mersana Therapeutics, Inc. (MRSN) Stock

$29.08 +0.00% NASDAQ: MRSN Healthcare

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs.

Valuation

MetricValue
Price$29.08
Market Cap$145.36M
P/E Ratio-2.59
P/B Ratio-2.44
P/S Ratio8.64
EPS (TTM)$-14.12
52-Week High$30.39
52-Week Low$5.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE116.96%
ROA-89.28%
ROCE-270.72%
Gross Margin98.29%
Operating Margin-312.53%
Net Margin-332.74%
Debt/Equity-0.04
Current Ratio1.39

Annual Financials (USD)

Metric20202021202220232024
Revenue$1.0M$0$27.0M$37.0M$40.0M
Operating Profit$-155.0M$-169.0M$-204.0M$-171.0M$-73.0M
Net Profit$-88.0M$-170.0M$-204.0M$-172.0M$-69.0M
EPS$-35.80$-60.24$-54.51$-36.96$-14.12
Op Margin-18737.4%-392693.0%-766.6%-463.9%-181.1%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$273.0M$206.0M$334.0M$226.0M$145.0M
Total Liabilities$45.0M$84.0M$242.0M$189.0M$154.0M
Cash$255.0M$178.0M$129.0M$175.0M$108.0M
Borrowings$17.0M$38.0M$36.0M$34.0M$29.0M

Latest News

A boutique AI cloud provider is bringing the direct listing back Pitchbook · Jul 16, 2026 US imposes new 25% tariffs on Brazil, expands exemptions list Reuters · Jul 16, 2026 ThredUp (TDUP): Buy, Sell, or Hold Post Q1 Earnings? StockStory · Jul 16, 2026 Franklin County Visitors Bureau is excited to announce 1864 Bourbon by Franklin County Distillery--Cold Spring Hollow PR Newswire · Jul 16, 2026 The $1,000 Hidden Tax on Every $10,000 Invested in This NVIDIA ETF 24/7 Wall St. · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-75.0M$-140.0M$-49.0M$-169.0M$-82.0M
Investing Cash Flow$37.0M$-1.0M$-155.0M$118.0M$11.0M
Financing Cash Flow$4.0M$2.0M$2.0M$1.0M$1.0M
Net Cash Flow$193.0M$-77.0M$-49.0M$46.0M$-67.0M
Free Cash Flow$-75.0M$-141.0M$-52.0M$-171.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.35
EV / EBITDA-1.71
FCF Yield-37.92%
Quick Ratio1.39
Interest Coverage-28.52
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics, Inc. is headquartered in US.

Mersana Therapeutics, Inc. (MRSN) stock trades at $29.08 with a market capitalization of $145.36M. The stock is valued at a price-to-earnings (P/E) ratio of -2.59, price-to-book of -2.44, price-to-sales of 8.64. Over the past 52 weeks the stock has ranged between $5.21 and $30.39, and currently trades 4.3% below its 52-week high.

On profitability, Mersana Therapeutics, Inc. generates a return on equity (ROE) of 116.96% — well above the market average, a sign of a high-quality business, return on capital employed of -270.72%, an operating margin of -312.53%, a net profit margin of -332.74%.

Official website: www.mersana.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides